List view / Grid view

Probiodrug AG

 

news

Promising preclinical findings for Probiodrug’s glutaminyl cyclase inhibitor

8 September 2016 | By Caroline Richards, Editor, European Pharmaceutical Review & Drug Target Review

In a mouse model of inflammation (thioglycollate-induced peritonitis), PQ912 had an effect on recruitment of macrophages and eosinophils, and levels of chemokines and lipid mediators, which the company believes makes QC inhibition attractive for further evaluation as potential anti-inflammatory drug and/or resolution promoting agent...